Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results

European Heart Journal Supplements : Journal of the European Society of Cardiology
Stefano SavonittoAntonia Maria Selva

Abstract

Patients with overt clinical atherosclerosis (ATS) or with previous peripheral vascular events have a high risk of ischaemic complications. A careful control of cardiovascular (CV) risk factors has been shown to improve prognosis, likely driven by a decrease progression of ATS. Prevention of occlusive complications is, on the other hand, based on antithrombotic therapy. So far, this therapeutic goal has been pursued through antiplatelet therapy with aspirin and P2Y12 receptor inhibitors. Anticoagulant therapy with full-dose vitamin K inhibitors, although effective in some arterial conditions, is burdened by high bleeding risk, and by low long-term compliance. In the COMPASS study, the association of aspirin with the factor Xa inhibitor, rivaroxaban, in a dose of one-fourth of the dose used in atrial fibrillation, decreased by more than 20% the incidence of CV events in patients with multi-district ATS. The positive effect was also observed as far as major peripheral complications, the like of critical limb ischaemia or limb amputations. This positive preventive effect was in addition to the effect of other preventive measures, such as the use of statins, ACE inhibitors, and aspirin itself. As compared to the aspirin-only treatm...Continue Reading

References

Oct 30, 2004·Stroke; a Journal of Cerebral Circulation·Pierre AmarencoPierre-Jean Touboul
Apr 25, 2015·Circulation Research·Michael H Criqui, Victor Aboyans
Apr 6, 2016·Journal of the American College of Cardiology·Marc P BonacaMarc S Sabatine
Dec 14, 2016·The New England Journal of Medicine·William R HiattUNKNOWN EUCLID Trial Steering Committee and Investigators
Aug 29, 2017·The New England Journal of Medicine·John W EikelboomUNKNOWN COMPASS Investigators
Sep 30, 2017·Journal of the American College of Cardiology·Carlo PatronoGemma Vilahur
Mar 16, 2018·Journal of the American College of Cardiology·Sonia S AnandSalim Yusuf
Jun 4, 2018·JAMA : the Journal of the American Medical Association·Connie N Hess, William R Hiatt
Aug 30, 2018·European Journal of Internal Medicine·Leonardo De LucaLeonardo Bolognese

❮ Previous
Next ❯

Citations

Jul 20, 2021·Hospital Practice·Grégoire DétrichéChloé Radureau

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
amputations

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.